Contraline Exercises License Option for NES/T, the First Male Contraceptive to Reach Late-Stage Development

Contraline, a clinical-stage biotechnology company developing novel male contraceptives, has exercised its option to exclusively license the Nestorone®/Testosterone (NES/T) gel from the Population Council.